98366-79-1

Usage

Uses

Used in Pharmaceutical Industry:
β-Cyclodextrin, 6A-deoxy-6A-[(2-methoxyethyl)amino](9CI) is used as a drug delivery agent for encapsulating and delivering hydrophobic drug molecules. The substitution with 2-methoxyethylamino on the β-Cyclodextrin molecule improves its solubility and stability, making it a potential candidate for the development of novel drug delivery systems.
Used in Food Processing Industry:
β-Cyclodextrin, 6A-deoxy-6A-[(2-methoxyethyl)amino](9CI) is used as a food additive to improve the stability and solubility of certain ingredients, enhancing the overall quality and shelf life of food products.
Used in Cosmetics Industry:
β-Cyclodextrin, 6A-deoxy-6A-[(2-methoxyethyl)amino](9CI) is used as a carrier for encapsulating and controlled release of bioactive compounds in cosmetic products, improving their efficacy and stability.

Upstream product

• 67217-55-4 mono-6-deoxy-6-(p-tolylsulphonyl)-β-cyclodextrin 
• 109-85-3 2-methoxyethylamine 

Relevant academic research and scientific papers

TIGHT INCLUSION OF AN ACID GUEST INTO THE CAVITY OF CYCLODEXTRIN BEARING AN AMINO MOIETY IN DIMETHYL SULFOXIDE

Circular dichroism measurements show that β-cyclodextrin with an amino moiety has a strong binding ability for ferrocenecarboxylic acid in dimethyl sulfoxide via an acid-base interaction.

NITRIC OXIDE-RELEASING CYCLODEXTRINS AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND METHODS PERTAINING THERETO

Disclosed herein are cyclodextrin molecules covalently modified to store and release nitric oxide, as well as methods of making and uses thereof. The covalently modified cyclodextrin molecules may be tailored, in several embodiments, to release nitric oxide in a controlled manner and are useful for reduction and/or eradication of bacteria and for the treatment of disease.

Nitric Oxide-Releasing Cyclodextrins

A series of secondary amine-modified cyclodextrin (CD) derivatives was synthesized with diverse exterior terminal groups (i.e., hydroxyl, methyl, methoxyl, and primary amine). Subsequent reaction with nitric oxide (NO) gas under alkaline conditions yieldedN-diazeniumdiolate-modified CD derivatives. Adjustable NO payloads (0.6-2.4 μmol/mg) and release half-lives (0.7-4.2 h) were achieved by regulating both the amount of secondary amine precursors and the functional groups around the NO donors. The bactericidal action of these NO-releasing cyclodextrin derivatives was evaluated againstPseudomonas aeruginosa, a Gram-negative pathogen, with antibacterial activity proving dependent on both the NO payload and exterior modification. Materials containing a high density of NO donors or primary amines exhibited the greatest ability to eradicateP. aeruginosa. Of the materials prepared, only the primary amine-terminated heptasubstituted CD derivatives exhibited toxicity against mammalian L929 mouse fibroblast cells. The NO donor-modified CD was also capable of delivering promethazine, a hydrophobic drug, thus demonstrating potential as a dual-drug-releasing therapeutic.